Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

← catalyst calendar

NCT06218914 · readout in 376 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

108estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-03-22

actual

When the study began enrolling

Primary completion

2027-08-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2043-11-18

estimated

The whole study's end, after follow-up

First posted

2024-01-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-28

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Non-small Cell Lung Cancer
Colorectal Carcinoma
Pancreatic Ductal Adenocarcinoma
Endometrial Cancer
Solid Tumor, Adult
KRAS G12D

Interventions

Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D
Biological: AZD0240: Autologous, engineered T Cells targeting KRAS G12D

Primary outcomes

what the primary-completion date above is the date OF

Part A (Dose Escalation): Evaluate the safety of KRAS TCRTs in subjects with unresectable, advanced, and/or metastatic solid tumors

measured Through study completion, an average of 2 years

Part A (Dose Escalation): Evaluate MTD and recommended dose for expansion (RDE)

measured 28 days after infusion

Part B (Expansion): Further evaluate the safety of KRAS TCRTs at the RDE in subjects with unresectable, advanced, and/or metastatic solid tumors

measured 28 days after infusion

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed